Clinical Trials Browser

Hormone Sensitive Prostate Cancer

Breast Neoplasms

HER2 Negative Breast Cancer

Castrate Sensitive Prostate Cancer

Breast Neoplasms

Breast Neoplasms, Sexual Dysfunctions, Psychological

Breast Neoplasms

PSA Level Greater Than Two

Prostatic Neoplasms

Advanced Breast Cancer

Breast Neoplasms, Breast Neoplasms, Male

Stage I Prostate Adenocarcinoma AJCC v7

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Adenocarcinoma

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Adenocarcinoma

Neoplasm Metastasis, Prostatic Neoplasms

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Breast Neoplasms

Salivary Gland Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

SELECT

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

preEMBER

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

A Study of Lerociclib in Participants With Advanced Breast Cancer

Adjuvant WIDER

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

DIVINE

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

VA STARPORT

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Roll-over Study to Allow Continued Access to Ribociclib

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

THUNDER

CARABELA

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer